Fidaxomicin · Regulatory approval

FDA approval: Fidaxomicin

U.S. Food and Drug Administration · August 13, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a generic fidaxomicin 200 mg tablet formulation by Sandoz under ANDA 220465 on 13 August 2026. This regulatory action confirms that the applicant met bioavailability, manufacturing, and safety standards for approval but does not itself report clinical efficacy, comparative benefit, or trial outcomes.

What was studied

Regulatory approval. Intervention: Fidaxomicin 200 mg tablet, oral formulation.

Key findings

FDA approval granted for fidaxomicin 200 mg tablet, oral formulation by Sandoz on 2026-08-13

Safety

The record does not specify the indication(s) approved, patient population studied in bioavailability trials, or safety profile details.

Who this may help

This approval enables access to a generic fidaxomicin option. Clinicians should rely on the established efficacy of fidaxomicin (from prior trials of brand-name formulations) when considering this generic alternative; this record does not report new efficacy or safety data.

Plain-language summary

FDA approval of a generic fidaxomicin formulation; regulatory action does not itself establish clinical efficacy or comparative benefit.

Study design

As stated by the source record.

InterventionFidaxomicin 200 mg tablet, oral formulation

Reported figures

Quoted from the source exactly as published.

Approved strength200 mg

Approval date2026-08-13

Clinical bottom line

Caveats

This regulatory record does not contain clinical trial results, efficacy data, or comparative effectiveness information.
The record does not specify the indication(s) approved, patient population studied in bioavailability trials, or safety profile details.
No sample size, trial duration, endpoints, or statistical results are reported.
Approval under ANDA (Abbreviated New Drug Application) is based on bioequivalence to a reference product, not de novo efficacy trials.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record only; no clinical trial design reported.

Directness

insufficient

Record does not report clinical outcomes or patient-relevant endpoints.

Consistency

insufficient

No comparison data or prior trial results cited in record.

Risk of bias

insufficient

Regulatory approval record; no bias assessment applicable or reported.

Sample adequacy

insufficient

No sample size or trial population data in approval record.

Source abstract

Drugs@FDA record for application ANDA220465. This is a regulatory action record, not a clinical study. Brand name: FIDAXOMICIN. Active ingredient: FIDAXOMICIN. Sponsor: SANDOZ. Submission type: ORIG (original application). Approval status date: 2026-08-13. Products: FIDAXOMICIN, TABLET, ORAL, FIDAXOMICIN 200MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

SandozFidaxomicin